Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ritonavir

ritonavir

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ritonavir

72 trials tracked of ritonavir: 21 in phase 3 or 4 and 6 with published results. The most-cited published study has 2162 citations.

72Trials tracked
21Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 15 Phase 2 33 Phase 1 13 Other / NA 5
  1. Phase 3 EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 Completed · 2,162 cited
  2. Phase 3 A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) Completed · 118 cited
  3. Phase 3 A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Completed · 34 cited
  4. Phase 3 Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Completed · 30 cited
  5. Phase 3 A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women Completed · 28 cited
  6. Phase 3 Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III Completed · 12 cited
Show 44 more trials
  1. Phase 4 Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection Completed
  2. Phase 4 Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women Completed
  3. Phase 4 Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients Completed
  4. Phase 4 Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin Completed
  5. Phase 4 Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function Completed
  6. Phase 4 Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment Completed
  7. Phase 3 TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV Completed
  8. Phase 3 Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults Completed
  9. Phase 3 Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients Completed
  10. Phase 3 A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects Completed
  11. Phase 3 GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men. Completed
  12. Phase 3 A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment Completed
  13. Phase 3 Comparative Study of Three NNRTI-Sparing HAART Regimens Completed
  14. Phase 3 GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection Completed
  15. Phase 3 Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults Completed
  16. Phase 2 Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Completed
  17. Phase 2 Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects Completed
  18. Phase 2 A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children Completed
  19. Phase 2 A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years Completed
  20. Phase 2 Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan Completed
  21. Phase 2 RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms Completed
  22. Phase 2 Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II Completed
  23. Phase 2 A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients Completed
  24. Phase 2 ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients Completed
  25. Phase 2 Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Completed
  26. Phase 2 Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. Completed
  27. Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects Completed
  28. Phase 2 Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients Completed
  29. Phase 2 Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents Completed
  30. Phase 2 A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Completed
  31. Phase 2 Study to Evaluate a HIV Drug for the Treatment of HIV Infection Completed
  32. Phase 2 An Interaction Study to Assess Drug Levels in Healthy Adult Subjects Completed
  33. Phase 2 48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection Completed
  34. Phase 2 Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) Completed
  35. Phase 2 Titrating-Dose of Lonafarnib in Combination With Ritonavir Completed
  36. Phase 2 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 Completed
  37. Phase 2 A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents Completed
  38. Phase 2 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) Completed
  39. Phase 2 Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen Completed
  40. Phase 2 A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children. Completed
  41. Phase 2 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed
  42. Phase 2 A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System Completed
  43. Phase 2 A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir Completed
  44. Phase 2 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Completed

Showing the 50 most-cited and recently-updated of 72 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nirmatrelvir/Ritonavir in Breast Milk: Low Infant Exposure in Lactating Women
Infectious Disease Phase I
Nirmatrelvir/Ritonavir in Breast Milk: Low Infant Exposure in Lactating Women Paxlovid levels low in breast milk, early study finds
This Phase 1 open-label study in 8 healthy lactating women found that nirmatrelvir/ritonavir concentrations in breast milk were consistently…
A small study finds that nirmatrelvir/ritonavir (Paxlovid) passes into breast milk at low levels, suggesting minimal infant exposure.
May 1, 2026
Nirmatrelvir-ritonavir showed no reduction in hospitalization or death within 28 days for higher-risk adults in community trials
Infectious Disease RCT
Nirmatrelvir-ritonavir showed no reduction in hospitalization or death within 28 days for higher-risk adults in community trials New Study Questions Early Use of Paxlovid for Vaccinated Patients
In community-based trials involving higher-risk adults with recent SARS-CoV-2 infection, adding nirmatrelvir-ritonavir to usual care did not…
Getting vaccinated changes how your body fights the virus, and this new research shows that taking Paxlovid early might not be necessary for…
Apr 23, 2026
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes
Pulmonology & Critical Care Cohort
Hospitalized COVID-19 patients receiving antiviral, antiretroviral, or immunosuppressive treatments showed variable outcomes What helps hospitalized COVID-19 patients survive? A new model offers clues
This cohort study of 711 hospitalized subjects with coronavirus evaluated antiviral, antiretroviral, and immunosuppressive treatments.
When COVID-19 hits hard, doctors need better tools to predict who might get worse.
medRxiv Apr 16, 2026
Nirmatrelvir-ritonavir reduced viral production by approximately 55% in SARS-CoV-2 BA.2-infected patients in Shanghai
Infectious Disease Cohort
Nirmatrelvir-ritonavir reduced viral production by approximately 55% in SARS-CoV-2 BA.2-infected patients in Shanghai Your COVID Pill May Work Better—Or Worse—Than You Think
This cohort study of 48,243 SARS-CoV-2 BA.2-infected patients in Shanghai evaluated nirmatrelvir-ritonavir exposure.
How well your Paxlovid works depends heavily on your age and vaccination status.
medRxiv Apr 13, 2026
Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19
Infectious Disease
Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19 Paxlovid prescription linked to lower hospitalization risk in adults with COVID-19
An observational study of eligible US adults with COVID-19 found those prescribed Paxlovid were 51% less likely to be hospitalized.
Adults prescribed Paxlovid for COVID-19 were 51% less likely to be hospitalized compared to those who did not get the medication.
CDC Apr 5, 2026
Clinical trials examine COVID-19 rebound after nirmatrelvir/ritonavir versus placebo treatment
Infectious Disease
Clinical trials examine COVID-19 rebound after nirmatrelvir/ritonavir versus placebo treatment Does the COVID-19 rebound risk change with or without Paxlovid treatment?
Randomized, double-blind trials at U.S. and international sites investigated COVID-19 rebound following nirmatrelvir/ritonavir treatment ver…
Two rigorous clinical trials are investigating whether Paxlovid treatment changes the risk of COVID-19 symptoms returning after patients sta…
CDC Apr 5, 2026
Observational study finds low hospitalization and ED visit rates after Paxlovid treatment for COVID-19 in California
Infectious Disease
Observational study finds low hospitalization and ED visit rates after Paxlovid treatment for COVID-19 in California Did Paxlovid keep COVID patients in California out of the hospital?
An observational study of patients in California treated with Paxlovid for COVID-19 reported low rates of subsequent hospitalizations and em…
Paxlovid treatment for COVID-19 in California was linked to low rates of hospitalizations and emergency department visits, offering hope for…
CDC Apr 5, 2026